The Fecal Microbiota Transplantation Registry
Launched by CHINESE UNIVERSITY OF HONG KONG · Dec 24, 2018
Trial Information
Current as of June 20, 2025
Recruiting
Keywords
ClinConnect Summary
The Fecal Microbiota Transplantation Registry is a clinical trial that is looking into the use of fecal microbiota transplantation (FMT) to help people with inflammatory bowel diseases (IBD). FMT involves taking stool from healthy donors and introducing it into patients, which can change the bacteria in the gut and potentially improve their condition. This trial aims to gather information about how the gut bacteria affect the progress of IBD and to understand the best ways to use FMT for these patients.
To participate in this study, you need to be at least 18 years old and either have received or are planning to receive FMT, or you can be a healthy donor willing to provide stool for transplantation. The trial is currently recruiting participants of all genders. If you decide to join, you can expect to share your experiences and help researchers learn more about the connection between gut bacteria and IBD. This information could lead to better treatment options for many patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18
- • Written informed consent obtained
- • Subject who has received or planning to receive FMT or other gut-related microbiota products in routine clinical practice or research (FMT recipents)
- • Subject who has donated stool or planning to donate stool for FMT or production of other gut-related microbiota products in routine clinical practice or research. Subjects who failed screening will also be recruited. (FMT donors)
- Exclusion Criteria:
- • Age ≤18
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Siew Chien Ng, PhD
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials